These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35978412)

  • 1. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Liu J; Tang G; Zhou Q; Kuang W
    Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram for Predicting Survival in Locally Advanced Cervical Cancer with Concurrent Chemoradiotherapy plus or Not Adjuvant Chemotherapy: A Retrospective Analysis Based on 2018 FIGO Staging.
    Hua L; Wei M; Feng C; Li S; Wen X; Chen S
    Cancer Biother Radiopharm; 2024 Nov; 39(9):690-705. PubMed ID: 38828494
    [No Abstract]   [Full Text] [Related]  

  • 4. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Para-aortic and pelvic lymphadenectomy in locally advanced cervical cancer with pelvic lymph node metastasis.
    Jiang W; Zhong ML; Wang SL; Chen Y; Wang YN; Zeng SY; Liang MR
    World J Surg Oncol; 2024 Sep; 22(1):262. PubMed ID: 39350212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
    Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
    Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
    J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T; Lingying W; Manni H; Jusheng A; Ning L
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.
    Chen JL; Huang CY; Huang YS; Chen RJ; Wang CW; Chen YH; Cheng JC; Cheng AL; Kuo SH
    Acta Obstet Gynecol Scand; 2014 Jul; 93(7):661-8. PubMed ID: 24666257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
    Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
    Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
    Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing survival outcomes between surgical and radiographic lymph node assessment in locally advanced cervical cancer: A propensity score-matched analysis.
    Yang J; Delara R; Magrina J; Magtibay P; Yi J; Langstraat C; Robertson M; Dinh T; Butler K
    Gynecol Oncol; 2020 Feb; 156(2):320-327. PubMed ID: 31843274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis.
    Wu SY; Huang EY; Chanchien CC; Lin H; Wang CJ; Sun LM; Chen HC; Fang FM; Hsu HC; Huang YJ
    J Radiat Res; 2014 Jan; 55(1):129-38. PubMed ID: 23814113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
    Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
    Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
    Liu C; Ran X; Wang Z; Zhang K
    Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
    Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.